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In the past, it was comparatively easier to mine and discover the key player genes and proteins associated with a 
particular disorder through literature survey. But in recent years the scientific research has attained its greatest pace resulting 
in the deposition of enormous molecular data over World Wide Web. Therefore, it is necessary to adopt specialized data 
mining methodologies and employ appropriate tools to reduce the ambiguous use of resources. In the present study, an 
attempt has been made to discover the most important genes and proteins involved in the Schizophrenia from all that have 
been reported till date by computing Average Normalized Database (AvNrD) scores of the genes. During the process, 
Dopamine receptor2 (DRD2), Serotonin receptor 2A (HTR2A) and Glutamate receptor 3 (GRM3) are found to be the most 
important proteins with significantly high AvNrD scores of 9.436725, 7.121672 and 7.709488 respectively out of 1229 
genes which are likely to be associated with Schizophrenia. Analysis of the filtered gene set reveals that most of the proteins 
possess specific G Protein Coupled Receptor (GPCR) signature sequences. DRD and HTR proteins consist of a long 
Intracellular 3 (IC3) region and GLU proteins consist of an extra N-terminal Extracellular (EC) domain. 
Keywords: Schizophrenia, Dopamine receptor, Serotonin receptor, Glutamate receptor, G protein coupled receptor, 
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Introduction 
Researches of several years have been focused in 
eradicating the diseases related to both physical as well 
as mental wellbeing which have led to tremendous 
important findings and hypothesis shedding light 
towards their diagnosis and treatment. Even though a 
greater degree of mystery has been solved for several 
disorders, disease like Schizophrenia seeks more 
profound and deeper research. Such problems exist due 
to the unpredictable phenotypic expressions of the 
disorder that lead to its unclear diagnosis on 
physiological as well as genetic basis.
1
 For this reason, 
the treatments are aimed at symptomatic relief rather 
than a complete cure. Schizophrenia patients are 
mainly diagnosed with hallucination, loss of focus, 
social distraction, confusion and sometimes aggression 
and suicidal tendency.
2
 In the present work, it is 
attempted to implement a novel experimental design 
through which all possible molecular level data could 
be explored on the complex brain disorder and 
thereafter the most important candidate genes could be 
recognized from the whole dataset obtained by merging 
the gene lists collected from 8 different databases. At 
the same time, we have tried to analyze the genes 
before and after each level of screening to evaluate 
their collective and comparative structural and 
functional aspects and interestingly arrived at some 
distinct findings that can be taken care of while dealing 
with further investigations on Schizophrenia. 
 
Materials and Methods 
 
Dataset preparation 
All possible genes involved in Schizophrenia were 
extracted from 8 different most widely used databases 
providing molecular information on any disorder based 





 provide gene list 
of any particular disorder based on the publications 
available through PUBMED. UniProt
5 
is a database 










 are databases of human 
genetic disorders. DrugBank
10
 is the database hosting 
drug data along with the corresponding target protein 
information. All these subsets of genes were merged to 
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form the superset containing all possible genes 
involved directly or indirectly with schizophrenia. 
 
Preparation of Reduced Dataset 
The first level of screening is applied to the datasets 
obtained from each database separately through 
STRING
11
 network analysis. The number of 2
nd
 order 
genes linked to each individual 1
st
 order gene was listed 
and only those genes with X > N where N = max(n)/3 
were selected for further consideration. Here ‘n’ is the 
Number of 2
nd
 order genes networked to each 1
st
 order 
gene and ‘X’ is the ‘n’ bellow which genes were 
excluded from each dataset. These filtered datasets are 
then merged. The second level of screening is executed 
by considering the scores obtained by normalizing the 
weightage scores of the individual databases. The 
average of these values was computed for each gene to 
obtain the AvNrD scores. 
 
Functional Classification and Domain prediction 
The first level filtered and merged dataset was 
made to undergo functional classification using the 
PANTHER
12 
database. This classification is based on 
the molecular functions and cellular localization of 
the proteins. GPCR regions present in the proteins 







 were used to establish the secondary 
structural elements and transmembrane boundaries 
after the second level of screening. Multiple Sequence 
Analysis of the GPCR signature region within similar 
proteins was done using CLUSTAL Omega
16
 through 
which the critical residues conserved in the case of the 
protein families could be identified. 
Three Dimensional structural analysis 
3D crystallographic structures of DRD2 (PDBID: 
6CM4), HTR2A (PDBID: 6a93), GRM3 (PDBID: 
4XAR) were extracted from PDB. As the structure of 
GRM available through PUBMED is incomplete, 
PHYRE 2
17
 server was used to predict the 3D structure 
of the complete GRM3 sequence. PHYRE 2is an 
automated tool for 3D structure prediction of proteins 
based on fold recognition. Galaxy refine
18
 was used for 
obtaining refined structures with comparatively more 
residues in the allowed region of Ramachandran plot. 
Predicted structures are validated using Procheck
19
 and 




Results and Discussion 
 
Preparation of the dataset 
A total of 1229 genes were obtained after merging 
the gene sets from eight different databases and 
removing data redundancy. Number of genes obtained 
from GWAS after taking P value ≤ 5 * 10
-8
is 399, 
from UniProt after restricting our search result to 
manually curated records only is 142, from GenAtlas 
after reducing our search results to records with valid 
Uniprot Ids is 200, from DisGeNET and GLAD4U 
with a cut off score >= 1 is 259 and 417 respectively, 
from GenCards and PharmaKb is 231 and 366 
respectively and from DrugBank after downloading 
80 drugs of Schizophrenia and finding their 
corresponding target proteins is 233 (Fig. 1).  
 
First tier screening of the genes 
By performing STRING network analysis of the 
gene sets of each database, we could clearly 
 
 
Fig. 1 — Number of genes in Complete and 1st tier filtered gene sets of different databases 




distinguish between the genes highly associated with 
Schizophrenia from that of less associated genes 
remaining as outliers in the network. After screening, 
we got 40, 31, 32, 32, 55, 54, 53 and 53 genes from 
GWAS, Uniprot, GenAtlas, DisGeNET, GLAD4U, 
PharmGKB, GenCards, and DrugBank respectively. 
The reduction in the dataset is clearly depicted in the 
graph shown in Fig. 1. Merging all these reduced gene 
sets created a subset of 166 genes. 
 
Protein classification 
While trying to classify the dataset generated in the 
previous step into different categories, it is found that 
the maximum number of proteins corresponding to the 
genes fall into the Receptor protein category displaying 
the highest peak in the graph shown in Fig. 2 followed 
by the Transporter protein category. 22 genes code for 
proteins falling into the Receptor category followed by 
16 genes coding for Transporter proteins. Further 
analysis of the receptor protein category revealed that 
most of the proteins in this category are GPCR proteins 
involved in the interaction with neurotransmitters. 
 
Second Tier screening of genes 
The scores representing the degree of relatedness 
of different genes/proteins with Schizophrenia are 
collected for each gene from GLAD4U, DisGeNET, 
GenCards, and DrugBank databases. A graph is 
plotted after computing AvNrD values within the 
weightage scores of the four databases. As shown in 
Fig. 3, DRD2 followed by HTR2A followed by 
GRM3 with an AvNrD score of 9.437, 7.709 and 
 
 





Fig. 3 — 2nd tier filtered genes/ proteins labeled in the graph: Dopamine, Serotonin & Glutamate receptors are found to be most important 
proteins with DRD2, HTR2A & GRM3 having significantly high score 




7.122 respectively are plotted as the most important 
genes strongly associated with Schizophrenia due to 
their highest peaks in the graph. This dataset 
contained 26 genes that includes all five Dopamine 
receptor protein coding genes (DRD1, DRD2, DRD3, 
DRD4, DRD5), five out of 17 Serotonin receptor 
protein coding genes (HTR1A, HTR1B, HTR2A, 
HTR2C, HTR7) and eleven out of 26 Glutamate 
receptor protein coding genes (GRIA1, GRIA2, 
GRIA4, GRIN1, GRIN2A, GRIN2B, GRM1, GRM2, 
GRM3, GRM4, GRM7). Within these three (GRIA1, 
GRIA2, GRIA4) out of 4are glutamate receptors 
ionotropic; AMPA, three (GRIN1, GRIN2A, 
GRIN2B) out of 7 are glutamate receptors ionotropic; 
NMDA and five (GRM1, GRM2, GRM3, GRM4, 
GRM7) out of 8 are metabotropic glutamate 
receptors. Apart from these, there are other five genes 
named as cannabinoid receptor1 (CNR1), glutamate 
decarboxylase1 (GAD1), sodium depended dopamine 
transporter (SLC6A3), sodium depended serotonin 
transporter (SLC6A4) and tyrosine 3-monooxygenase 
(TH) also found within the group (Fig. 3).  
 
GPCR and Transmembrane domain prediction 
Analyzing the conserved domains present in all the 
26 proteins revealed that 18 out of 26 proteins are 
having G-protein coupled receptor protein (GPCR) 
domain within them consisting of seven 
Transmembranes (TM). Table 1 summarizes all the 
GPCR features present and absent in the protein 
sequences. One disulfide bond is present in the case 
of dopamine and serotonin receptors which is 
completely absent in glutamate receptors and SLC 
receptors. The GPCR spanning region is longest in 
SLC proteins ranging between 524 aa to 526 aa 
whereas it is smallest in case of GRM proteins 
ranging between 262 aa to 274 aa. The GPCR range 
in HTR proteins is 289 aa to 347 aa and that of DRD 
proteins is 280 aa to 397 aa. 
As demonstrated in Fig. 4, the conserved GPCR 
signature substring in DRD proteins is ASI(f/l)NLC 
(A/V)IS(V/I)DR(F/Y)(V/W/T)a(V/I). TM1, TM2, 
TM3, TM4, TM5, TM6 and TM7 of DRD2 falls 
between 37 to 61, 71 to 98, 109 to 131, 152 to 174, 
187 to 216, 374 to 398 and 408 to 429 amino acid 
positions. Cys-Cys disulfide bond is present between 
IC1 and IC2 in DRD2 (Fig. 4). Similarly the GPCR 
signature sequence in HTR proteins as predicted using 
MSA of Clustal omega is (A/S)SI(m/l)(T/H) 
LC(V/A)I(S/A)(I/L)DRY(L/W/V)(g/a)I and in GRM 
proteins is FNEAK(y/f/p)I(A/G)FTM. The SLC 




Three Dimensional structures of DRD2, HTR2A, and GRM3 
The crystal structure recombinant DRD2 with T4 
Lysozyme (DRD2R-T4L) construct is present in PDB 
 
Table 1 — GPCR region prediction using PROSITE 
Proteins GPCR Range Disulfide bridge Signature Range Signature sequence 
CNR1 133–397 189–264 202–218 ASVgSLFLTAIDRYIsI 
DRD1 40–331 96–186 109–125 ASIlNLCVISVDRYWaI 
DRD2 51–426 107–182 120–136 ASIlNLCAISIDRYTaV 
DRD3 46–383 103–181 116–132 ASIlNLCAISIDRYTaV 
DRD4 51–448 108–185 121–137 ASIfNLCAISVDRFVaV 
DRD5 57–359 113–217 126–142 ASIlNLCVISVDRYWaI 
GRM1 592–854 Absent 781–791 FNEAKyIAFTM 
GRM2 567–833 Absent 756–766 FNEAKfIGFTM 
GRM3 576–842 Absent 765–775 FNEAKfIGFTM 
GRM4 587–861 Absent 781–791 FNEAKpIGFTM 
GRM7 590–864 Absent 784–794 FNEAKpIGFTM 
HTR1A 53–400 109–187 122–138 SSIlHLCAIALDRYWaI 
HTR1B 66–369 122–199 135–151 ASIlHLCVIALDRYWaI 
HTR2A 91–380 148–227 161–177 ASImHLCAISLDRYVaI 
HTR2C 70–368 127–207 140–156 ASImHLCAISLDRYVaI 
HTR7 98–384 155–231 168–184 ASImTLCVISIDRYLgI 
SLC6A3 59–585 Absent 84–98 WRFPYlcykNGGGaF 
   166–186 YLfsSFTteLPWihCnnswNS 
SLC6A4 78–602 Absent 103–117 WRFPYicyqNGGGaF 
   186–206 YLisSFTdqLPWtsCknswNT 
 




(6CM4: 2.87 Å resolution). The engineered sequence 
of this construct is manually modified at several 
positions to achieve a higher degree of expression, 
purification and crystallization. The wild type 
sequence is truncated from 1 to 34 position. Amino 
acids Isoleucine at position 22 and leucine at position 
375 & 379 are mutated to Alanine [I122A; L375A; 
L379A]. Stretch of wild type sequence starting from 
Valine at 223 position up toArginineat 380 position 
[V223-R361] is replaced by 159 amino acid long T4 
lysozyme sequence [T4L(2-161)] (Fig. 5). 
The structure of recombinant HTR2A with mutated 
Apo cytochrome of E coli (HTR2AR-mbIIG) is 
available at PDB (6a93: 3.0 Å resolution). This 
structure is obtained by deleting 1 to 69 amino acids 
and 404 to 471 amino acids from N and C terminals 
respectively, by performing Serine to Lysine at 162 
position and Methionine to Tryptophan [S162K; 
M164W] thermostabilizing mutations and by 
replacingthe sequence from Threonine at position 266 
up to Methionine at position 312 [T266-M312] with 
mutated sequence of b562IIG. The mutated b56IIG is 
generated by mutating Methionine to Tryptophan at 
position 7, Arginine to Isoleucine at position 98, 
Histidine to Isoleucine at position 102, Arginine to 
Glycineat position 106 [M7W; R98I; H102I; R106G] 
 
 
Fig. 4 — GPCR and Transmembrane domain analysis of DRD2: A. Amino acid sequence comprising the GPCR region are marked in 
blue; Transmembrane regions are underlined in green; GPCR signature sequence patch is shown in multiple color; Cys residues forming 
disulfide bond are highlighted in yellow. B. Cartoon figure indicating the transmembrane boundaries are shown along with the other 




Fig. 5 — A. 3D structures of recombinant Dopamine receptor with T4 Lysozyme (DRD2R-T4L) B. 3D structures of recombinant 
serotonin receptor 2A with mutated Apo cytochrome of HTR2AR-mbIIG. C. 3D structures of GRM3 predicted using Phyre2 




and by replacing loop region from Glutamine at  
41 position to Phenylalanine at position 62 [Q41-F62] 
by [Gly-Ser-Gly-Ser-Gly] (Fig. 5). 
The 3D structure of the extracellular catalytic 
domain of GRM3 is available at Protein Data Bank 
(4XAR: 2.6 Å resolution). The sequence of this PDB 
structure spans only between 2 to 508 on the wild 
type sequence. Its N terminal consists of extra 
Methionine, Alanine and Lysine [MAK] and C 
terminal consists of Histidine tag (Gly-His-His-His-
His-His-His). The complete structure of GRM3 
predicted through Phyre2 and refined through Galaxy 
Refine is placed in Fig. 5c, where the two domains 
(one glutamate binding domain or extracellular 
catalytic domain and another Transmembrane GPCR 
domain) are distinctly labeled. This sequence spans 
between 30 to 831 position on wild type sequence out 
of which 1 to 510 forms glutamate binding domain 
and 565 to 831 forms the GPCR domain. The 
complete structure of GRM3 is having 92.4% of 
amino acid residues in the allowed region, 7.2% in the 
additionally allowed region, 0.4% (Ala487, His498, 
Val798) in the generously allowed region and 0.0% in 
the disallowed region of Ramachandran plot. 
 
Conclusion 
The complete work is dedicated to reveal the major 
key player genes and thence their corresponding 
proteins involved in schizophrenia and make an 
analysis of these gene sets to reveal and recognize if 
any common and/or specific structural and functional 
features are shared by them. After applying all 
prediction methods, we could clearly observe that the 
majority of the genes code for Transmembrane GPCR 
proteins involved in the regulation and movement of 
neurotransmitters. The majority of the proteins have a 
short GPCR signature sequence pattern conserved 
within the protein families. Along with 7 TM helices 
that are embedded within the cell membrane in case of 
most of the proteins, the dopamine receptor proteins 
and serotonin receptor proteins have a long variable 
IC3 region whereas glutamate receptor proteins have a 
large extracellular N-terminal region. Both DRD and 
HTR proteins have a DRY(Asp-Arg-Tyr) conserved 
sites and a disulfide Cys-Cys double bond which is 
absent in GRM proteins. DRD2, HTR2A and GRM3 
are found to have significantly higher AvNrD score 
within the 26 genes that have been identified after two 
levels of screening. The 3-D structures of the GPCR 
regions of the proteins were found and refined to 
achieve maximum accuracy. Effect of mutations on the 
structural and functional stabilities of these proteins 
and their corresponding contribution towards the cause 
of the disorder along with the study of the 
Schizophrenia drugs interacting with the proteins are 
under our concern for our upcoming research works.  
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